SPAC Deal for Bull Horn and Cancer Cell Therapy Specialist Coeptis Therapeutics

by | Apr 19, 2022

SPAC Deal for BHSE and Cancer cell therapy biopharma Coeptis. Merger votes for Tempo Automation and Telesign. And the rest of the day’s news in SPACs.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

SPAC Deal: BHSE + Coeptis Therapeutics (OTC PINK: COEP)

Bull Horn Holdings Corp. (BHSE) announced a merger agreement with Coeptis Therapeutics, a biopharmaceutical company developing cell therapy platforms for cancer. Holders of Coeptis shares will receive equity in Bull Horn valued at $175 million (subject to adjustments). No PIPE. The transaction is expected to close in the third quarter 2022. Coeptis Therapeutics is expected to list on Nasdaq under the ticker symbol “COEP.” BHSE has a 5/3 deadline and a looming 4/26 extension vote out to November. Current NAV of $10.10 would be ~$10.30 if it goes to November. ($0.033 contribution per month) or up to ~$0.20.

Merger vote set for ACEV / Tempo Automation

ACE Convergence Acquisition Corp (ACEV) sets 5.5 as vote date on merger with Tempo Automation (TMPO).

Merger vote set for NAAC / Telesign

North Atlantic Acquisition Corporation (NAAC) sets 5.18 vote date for merger with Telesign, a maker of enterprise Digital Identity and CPaaS (Communications Platform as a Service) software.

Elsewhere in SPACs

Biggest Gainers

2.54% ~ $ 48.81 | DWAC – Digital World Acquisition Corp. (Announced)
1.94% ~ $ 12.08 | GGPI – Gores Guggenheim, Inc (Announced)
1.56% ~ $ 10.40 | IPOD – Social Capital Hedosophia Holdings Corp IV (Pre-Deal)
1.43% ~ $ 11.32 | CFVI – CF Acquisition Corp. VI (Announced)
1.43% ~ $ 10.65 | IPOF – Social Capital Hedosophia Holdings Corp VI (Pre-Deal)
1.12% ~ $ 10.80 | THCA – Tuscan Holdings Corp. II (Pre-Deal)
1.01% ~ $ 10.01 | MEAC – Mercury Ecommerce Acquisition Corp (Pre-Deal)
.82% ~ $ 9.81 | SCAQ – Stratim Cloud Acquisition Corp. (Pre-Deal)
.71% ~ $ 9.88 | OEPW – One Equity Partners Open Water I Corp. (Pre-Deal)
.70% ~ $ 10.04 | CPAQ – Counter Press Acquisition Corp (Pre-Deal)
.62% ~ $ 9.77 | GFGD – Growth for Good Acquisition Corp (Pre-Deal)
.60% ~ $ 9.99 | AEAE – AltEnergy Acquisition Corp (Pre-Deal)
.60% ~ $ 10.00 | DYNS – Dynamics Special Purpose Corp. (Announced)
.60% ~ $ 10.04 | SHCA – Spindletop Health Acquisition Corp. (Pre-Deal)
.51% ~ $ 9.85 | DGNU – Dragoneer Growth Opportunities Corp. III (Pre-Deal)
.51% ~ $ 9.92 | ROCL – Roth CH Acquisition V Co. (Pre-Deal)
.51% ~ $ 9.94 | NAAC – North Atlantic Acquisition Corporation (Announced)
.50% ~ $ 9.96 | BRD – Beard Energy Transition Acquisition Corp. (Pre-Deal)
.50% ~ $ 9.97 | BIOS – BioPlus Acquisition Corp. (Pre-Deal)
.47% ~ $ 9.92 | ASCA – ASPAC I Acquisition Corp. (Pre-Deal)

Biggest Losers

-4.74% ~ $ 10.45 | SV – Spring Valley Acquisition Corp (Announced)
-2.76% ~ $ 9.88 | CHWA – CHW Acquisition Corp (Announced)
-1.28% ~ $ 10.84 | ESSC – East Stone Acquisition Corporation (Announced)
-1.23% ~ $ 10.41 | MEKA – MELI Kaszek Pioneer Corp (Pre-Deal)
-.69% ~ $ 10.10 | LCAP – Lionheart Acquisition Corporation II (Announced)
-.51% ~ $ 9.85 | IIII – INSU Acquisition Corp. III (Pre-Deal)
-.50% ~ $ 9.93 | WNNR – Andretti Acquisition Corp. (Pre-Deal)
-.50% ~ $ 9.93 | HSAQ – Health Sciences Acquisitions Corporation 2 (Pre-Deal)
-.41% ~ $ 9.78 | DTOC – Digital Transformation Opportunities Corp. (Pre-Deal)
-.41% ~ $ 9.81 | VTIQ – VectoIQ Acquisition Corp. II (Pre-Deal)
-.41% ~ $ 9.81 | AMCI – AMCI Acquisition Corp. II (Announced)
-.41% ~ $ 9.82 | DLCA – Deep Lake Capital Acquisition Corp. (Pre-Deal)
-.41% ~ $ 9.83 | FINM – Marlin Technology Corp (Pre-Deal)
-.40% ~ $ 9.90 | PACI – PROOF Acquisition Corp I (Pre-Deal)
-.40% ~ $ 9.94 | TRAQ – Trine II Acquisition Corp (Pre-Deal)
-.40% ~ $ 10.03 | ACTD – ArcLight Clean Transition Corp. II (Announced)
-.31% ~ $ 9.87 | NFNT – Infinite Acquisition Corp. (Pre-Deal)
-.31% ~ $ 9.79 | ATVC – Tribe Capital Growth Corp I (Pre-Deal)
-.30% ~ $ 9.81 | THCP – Thunder Bridge Capital Partners IV, Inc. (Announced)
-.30% ~ $ 9.81 | TCOA – Trajectory Alpha Acquisition Corp. (Pre-Deal)

Upcoming Merger and Extension Votes

Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Recent Analysis

Weekly Activism & Executive Moves Review (April 12)

Macy’s and Arkhouse / Brigade enter an agreement, but the fight isn’t over yet. Illumina gets a new CFO as shareholders wait for Icahn’s directors to change trajectory. ANGI gets a new CEO as IAC CEO Levin steps aside.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.